[ad_1]
Hepabig-jean is an immunoglobulin preparation, different from the conventional method of blood separation (plasma), and is known to be a drug with higher antibody purity and excellent ability to neutralize the virus thanks to recombinant gene technology. GC Green Cross has developed hepafacaine as a preventive measure against the recurrence of hepatitis B in patients with hepatitis B, as well as in clinical trials on chronic treatment of hepatitis B.
In this announcement, the efficacy and safety results of hepatocell versus dose for the treatment of chronic hepatitis B were disclosed. Hepigzin did not show any significant adverse effect when the dose was maximized. The doses and duration of significant reduction of hepatitis B surface antigen have also been determined.
The pharmaceutical industry notes that hepabigzine is not a form of antiviral agent different from that commonly used in the treatment of hepatitis B, but that the combination of hepatitis B and antiviral drugs can optimize the treatment of hepatitis B. Ahn Sang-hoon, professor of clinical medicine at Yonsei University Hospital, said: "We have been able to maximize the level of treatment of chronic hepatitis B, we will study more before the way to maximize the treatment through the badociation treatment "
The number of chronic hepatitis B patients worldwide is estimated at 300 million, and among them, the disease worsens, resulting in cirrhosis and liver cancer, killing about 780,000 people a year .
[서진우 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]Source link
